Öз½±±¾©/ÃÀ·½ÐÂÔóÎ÷Öݲ¼ÀïÆæÎÖÌØ2021.4.6ÈÕ— È«ÇòÉúÎïÖÆÒ©ÀÖÓãÓÎÏ·ÀÖÓãÓÎÏ·¹É·ÝÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ:ÀÖÓãÓÎÏ·¹ÉƱ´úÂë:603087.SH£©µ±ÌìÐû²¼Å·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©¹Â¶ùҩίԱ»áÊÚÓèÑо¿Ò©ÎïGLR2007¹Â¶ùÒ©×ʸñÈ϶¨ÓÃÓÚ½ºÖÊÁöµÄÖÎÁÆ.
½ºÖÊÁöÊÇÖ¸Ô´×ÔÖÐÊàÉñ¾ÏµÍ³½ºÖÊϸ°ûµÄÉñ¾ÉÏƤÖ×ÁöÊÇ1ÖÖʵÌåÖ×Áö°üÀ¨ÐÇÐÎϸ°ûÖ×Áö(ÀýÈ罺ÖÊĸϸ°ûÁöGBM).GBMÊÇ×î¾ßÇÖÏ®ÐÔµÄÔ·¢ÐÔÄÔÖ×ÁöÖ®1¾¡¹Üͨ¹ýÊÖÊõ .»¯ÁƺͷÅÉäÖÎÁÆÄÜÈ¡µÃ1¶¨ÁÆЧ1µ«»¼ÕßµÄÖÐλÉú´æÆÚ½öΪ12ÖÁ15¸ö..ÀÖÓãÓÎÏ·Ä¿Ç°ÕýÓÚÁÙ´²Ñз¢µÄGLR2007ÊÇ1¿îϸ°ûÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸4/6£¨CDK4/6£©ÒÖÖƼÁ¿ÉÄÜ×÷ΪÍíÆÚʵÌåÖ×ÁöÖÎÁƵÄÁí1ÖÖÁÆ·¨Ñ¡Ôñ.
ÀÖÓãÓÎÏ·GLR2007µÄ1ÆÚÁÙ´²ÊÔÑ飨NCT04444427£©Ä¿Ç°Õý´¦ÓÚ»¼ÕßÈë×é½×¶ÎÖ¼ÓÚÑо¿GLR2007ÓÚÍíÆÚʵÌåÖ×Áö»¼ÕßÌåÄÚµÄÒ©ÎﰲȫÐÔ .ÄÍÊÜÐÔ¼°×î¼Ñ¸øÒ©²ßÂÔ.ÀÖÓãÓÎÏ·Å·ÃÀҽѧÊÂÎñ²¿¸ºÔðÈËMichelle Mazuranic±íʾ“´Ë´Î»ñµÃEMA¹Â¶ùÒ©×ʸñÈ϶¨ÊǼÌGLR2007»ñµÃÃÀ·½Ê³Æ·Ò©Æ·¼à¶½¹ÜÀí¾Ö£¨FDA£©ÊÚÓèµÄ¹Â¶ùÒ©×ʸñÈ϶¨Ö®ºóµÄÓÖ1ÖØ´óÍ»ÆÆ”.
Å·ÃË£¨EU£©µÄ¹Â¶ùÒ©×ʸñÈ϶¨ÊǸù¾ÝÅ·ÃËίԱ»á¸ù¾ÝÅ·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©¹Â¶ùҩίԱ»á£¨COMP£©¸ø³öµÄ¿Ï¶¨Òâ¼ûÊÚÓèµÄ×ʸñÈ϶¨.»ñÆÀ×ʸñÒªÇóÓÚÑÐÒ©Îï±ØÐëÖ¼ÓÚÖÎÁƼ«¶ÈË¥ÈõÐÔ»òΣ¼°ÉúÃüµÄº±¼û².¨Å·ÃË»¼²¡Âʲ»³¬¹ý5/10000µÄ¼²².©ÇÒ±ØÐëÓÐ×ã¹»µÄ·ÇÁÙ´²»òÁÙ´²Êý¾Ý±íÃ÷¸ÃÒ©Îï¿ÉÒÔ²úÉúÁÙ´²ÁÆЧ²¢ÓµÓбÈÄ¿Ç°»ñÅúµÄ²úÆ·¸ü´óÊÕÒæµÄDZÁ¦.Å·ÃËEMA¹Â¶ùÒ©×ʸñÈ϶¨ÎªÖÆÒ©¹«Ë¾ÌṩÁË1¶¨µÄ¼¤Àø´ëÊ©°üÀ¨»ñÅúºó10.ÄÚµÄÊг`ÀռȨ .ÁÙ´²·½°¸ÐÖú .¹ú¼Ò¼ä²îÒ컯ÎÀÉú¼¼ÊõÆÀ¹ÀÁ÷³Ì¼°Å·Ã˳ÉÔ±¹úͳ1ÓªÏúÊÚȨ.
Èç¹ûÄúÏëÁ˽â¸ü¶àGLR2007ÁÙ´²Ñо¿ÐÅÏ¢Çë·ÃÎÊ:
https://clinicaltrials.gov/ct2/show/NCT04444427?term=glr2007&draw=2&rank=1
²Î¿¼ÎÄÏ×
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., Jaeckle, K. A., Scheithauer, B. W., Dancey, J., Hidalgo, M., Walsh, D. J., & North Central Cancer Treatment Group (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(23), 5294–5304. https://doi.org/10.1200/JCO.2005.23.622
¹ØÓÚÀÖÓãÓÎÏ·
ÀÖÓãÓÎÏ·¹É·ÝÓÐÏÞ¹«Ë¾£¨¼ò³Æ:ÀÖÓãÓÎÏ·¹ÉƱ´úÂë:603087.SH£©×÷ΪÖз½µÚ1¼ÒÕÆÎÕ²úÒµ»¯Éú²úÖØ×éÒȵºËØÀàËÆÎï¼¼ÊõµÄ¸ß¿Æ¼¼ÉúÎïÖÆÒ©ÀÖÓãÓÎÏ·¾ß±¸ÍêÕûÒȵºËØÑз¢¹ÜÏß.Ä¿Ç°¹«Ë¾ÒÑÓµÓг¤Ð§¸Ê¾«ÒȵºËØ×¢ÉäÒº£¨³¤ÐãÁØ®£© .ËÙЧÀµ¸¬ÒȵºËØ×¢ÉäÒº£¨ËÙÐãÁØ®£©¼°ÃŶ¬ÒȵºËØ×¢ÉäÒº£¨ÈñÐãÁØ®£© .Ô¤»ì¾«µ°°×пÖØ×éÀµ¸¬ÒȵºËØ»ìºÏ×¢ÉäÒº£¨25R£©£¨ËÙÐãÁØ® 25£©¼°ÃŶ¬ÒȵºËØ30×¢ÉäÒº£¨ÈñÐãÁØ® 30£©5¸öÖØ×éÒȵºËØÀàËÆÎïÆ·ÖÖ .¿ÉÖظ´Ê¹ÓõÄÒȵºËØ×¢Éä±Ê£¨ÐãÁرʮ£©ºÍ1´ÎÐÔ×¢Éä±ÊÓÃÕëÍ·£¨ÐãÁØÕ뮣©²úÆ·¸²¸Ç³¤Ð§ .ËÙЧ .ÖÐЧ3¸öÒȵºËع¦ÄÜϸ·ÖÊг¡.
ÓÚδÀ´ÀÖÓãÓÎÏ·½«ÊµÏÖÓÚÌÇÄò²¡Õï¶ÏºÍÖÎÁÆÁìÓò²úÆ·ÏßÈ«Ã渲¸Ç½ø1²½ÌáÉý¹«Ë¾ÓÚÌÇÄò²¡ÖÎÁÆÁìÓòµÄÊг[ºÕùÁ¦.¹«Ë¾»¹½«»ý¼«Í¶Èëµ½»¯Ñ§Ò© .ÕæºË¼°ÔºËµ°°×Öʹ¤³Ì .Ö×ÁöºÍÐÄѪ¹Ü¼°´úл²¡µÈÑо¿ÁìÓò.